HomeNewsBusinessCompaniesClinigene & Syngene may list in a year's time: Biocon

Trending Topics

LG Electronics IPO Allotment Status

Canara HSBC Life IPO GMP

Midwest IPO Price

WeWork Share Price

Silver ETF

Clinigene & Syngene may list in a year's time: Biocon

In an exclusive interview with CNBC-TV 18, Kiran Mazumdar Shaw, CMD of Biocon says that Clingene & Syngene to undergo transformation in the business model and would wait for a year before listing the IPO. She also expects Pfizer revenues in the next 24-36 months.

January 04, 2011 / 11:14 IST

Story continues below Advertisement

Your browser doesn't support HTML5 video.

Pharma major Biocon

TAGS: #Biocon #Business #Clinigene #Kiran Mazumdar #Pfizer #Syngene

first published: Jan 3, 2011 10:59 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On:

instagram

youtube

News

Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New

Features

Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube

Tools

SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4

Specials

PowerYourTrade Master Your Money Game Changers

Network 18 Sites

News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18

Personal Finance

Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator

Quick Links

About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New

Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.